Skopos Labs, Inc. Allogene Therapeutics, Inc. Transaction History
Skopos Labs, Inc.
- $453 Million
- Q1 2025
A detailed history of Skopos Labs, Inc. transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Skopos Labs, Inc. holds 30,731 shares of ALLO stock, worth $32,574. This represents 0.01% of its overall portfolio holdings.
Number of Shares
30,731Holding current value
$32,574% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding ALLO
# of Institutions
176Shares Held
165MCall Options Held
202KPut Options Held
76.6K-
Tpg Gp A, LLC Fort Worth, TX18.7MShares$19.8 Million0.84% of portfolio
-
Black Rock Inc. New York, NY16.4MShares$17.4 Million0.0% of portfolio
-
Capital World Investors Los Angeles, CA12.3MShares$13 Million0.0% of portfolio
-
Lynx1 Capital Management LP San Juan, PR11.1MShares$11.7 Million5.97% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y910.4MShares$11.1 Million1.06% of portfolio
About Allogene Therapeutics, Inc.
- Ticker ALLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 143,807,008
- Market Cap $152M
- Description
- Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...